Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Developing a patient pathway to deliver a new oral chemotherapy

Capecitabine (Xeloda, Roche) is an oral chemotherapy drug developed for use in place of some intravenous chemotherapy regimens in specific cancers and it is important, as with intravenous (IV) chemotherapy regimens, to carry out a toxicity assessment and to provide patients with support. This paper explores a service development in St Luke’s Cancer Centre, Surrey and in the Surrey, West Sussex and Hampshire Cancer Network that involved introduction of this new oral chemotherapy agent.

Subscribe for full online access and get...

  • Full, instant access to all stories
  • Customised email alerts straight to your inbox
  • 5,000+ practice articles in our clinical archive
  • Online learning units on fundamental aspects of nursing care

Register for guest access to keep reading and get...

  • A free taste of other selected news stories
  • Daily email newsletters

Speak with a member of the team about providing Nursing Times for your whole team
Are you a student nurse? Take advantage of a discounted rate by clicking here (Graduation date required)
Already have an account? Sign in